Back to Search
Start Over
Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial
- Source :
- Odderskov, C, Stengaard-Pedersen, K, Ellingsen, T & Hornung, N 2020, ' Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 80, no. 3, pp. 185-190 . https://doi.org/10.1080/00365513.2019.1706190, Odderskov, C, Stengaard-Pedersen, K, Ellingsen, T & Hornung, N 2020, ' Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial ', Scandinavian Journal of Clinical and Laboratory Investigation, vol. 80, no. 3, pp. 185-190 . https://doi.org/10.1080/00365513.2019.1706190
- Publication Year :
- 2019
- Publisher :
- Informa UK Limited, 2019.
-
Abstract
- The aim was to investigate if the pharmacokinetics of methotrexate (MTX) are affected by the addition of cyclosporin (CsA). Forty patients diagnosed with early rheumatoid arthritis (RA) were included in this open prospective study: 20 patients were treated with a dose of 7.5 mg MTX and a dose of 2.5 mg/kg CsA, 20 patients were treated with a dose of 7.5 mg MTX and placebo. Baseline measurements of plasma MTX and erythrocyte MTX were made. Area under the plasma concentration versus time curve (AUC) and other pharmacokinetic variables were estimated by means of a population based software model. Clinical improvement of 20-50-70% according to the American College of Rheumatology (ACR) and adverse events were evaluated ongoing for 52 weeks. We found that mean peak plasma MTX concentration was significantly higher in the MTX + CsA combination treatment group (p = .003). No differences in AUC, erythrocyte MTX or other pharmacokinetic parameters were found between the two treatment groups. Estimated Glomerular Filtration Rate (eGFR) decreased significantly in the MTX + CsA treatment group (p < .001), but no serious adverse events occurred in either of the two groups. In conclusion, CsA added to methotrexate treatment in early RA significantly increased peak-plasma MTX concentration, but other pharmacokinetic parameters and measurements of MTX were unchanged.
- Subjects :
- Adult
Male
musculoskeletal diseases
medicine.medical_specialty
Erythrocytes
Clinical Biochemistry
Gastroenterology
methotrexate
Drug Administration Schedule
law.invention
Arthritis, Rheumatoid
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
Randomized controlled trial
Pharmacokinetics
immune system diseases
law
Internal medicine
medicine
Humans
heterocyclic compounds
cyclosporine
030212 general & internal medicine
pharmacokinetic
Rheumatoid arthritis
skin and connective tissue diseases
Aged
030203 arthritis & rheumatology
business.industry
General Medicine
Early rheumatoid arthritis
Middle Aged
medicine.disease
Early Diagnosis
Methotrexate
Treatment Outcome
Antirheumatic Agents
Area Under Curve
Cyclosporine
Female
business
Glomerular Filtration Rate
Co administration
medicine.drug
Subjects
Details
- ISSN :
- 15027686 and 00365513
- Volume :
- 80
- Database :
- OpenAIRE
- Journal :
- Scandinavian Journal of Clinical and Laboratory Investigation
- Accession number :
- edsair.doi.dedup.....12e5bb524c7ec429b777912dd0134cea